Sarcoma Clinical Trials
Patients with sarcoma can consider clinical trials to expand their range of treatment options. In a clinical trial, researchers provide one group of patients with an investigational therapy, such as a novel chemotherapy drug, while providing a second group of patients with the best treatment that is currently available. This helps patients access the newest treatments before they are offered to the public, while helping researchers determine which treatments produce the best outcomes and the fewest side effects.
The Only Florida-based NCI-designated Comprehensive Cancer Center
Recognized for its scientific excellence, Moffitt is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.
Recent sarcoma clinical trials have investigated treatments such as:
- New medications for chemotherapy-resistant sarcomas
- New drug combinations for sarcomas that cannot be surgically removed
- Proton therapy as an alternative to X-ray-based radiation therapy
- Peripheral stem cell transplantation as a potential sarcoma treatment
- Antibody-based treatments for recurrent sarcomas
- Less toxic treatments for pediatric sarcoma patients
Other sarcoma clinical trials have explored risk factors, screening methods, preventive options and techniques to improve the likelihood of early diagnosis. For instance, researchers have linked several genetic syndromes to an increased risk of developing sarcoma, and this information has led to better awareness for these individuals. Through clinical trials, researchers are improving options not just for current patients, but for every individual who will face a sarcoma diagnosis in the future.
As part of our commitment to ongoing research, Moffitt Cancer Center offers an extensive range of clinical trials, with options for patients with many different types and stages of sarcoma. These trials are overseen by our expert oncologists and research professionals; careful monitoring ensures that every participant receives the best possible treatment for his or her needs. In recognition of our extensive research efforts, the National Cancer Institute awarded Moffitt Cancer Center with its prestigious Comprehensive Cancer Center designation.
For more information about sarcoma clinical trials, or to enroll in one of Moffitt Cancer Center’s ongoing trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Referrals are not required to seek treatment at Moffitt and participate in our clinical trials.
Helpful Links:
-
Clinical Trials
CLINICAL TRIAL 21136
Phase 2 Clinical Trial of Radiomic Habitat-Directed Radiation Dose Escalation for High-Grade Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Radiotherapy ()
CLINICAL TRIAL 22294
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); DTIC (Dacarbazine); Dacarbazine (); Ifosfamide (); Not Applicable (); doxorubicin ()
CLINICAL TRIAL 23281
Metastatic Ewing s Trial Testing Schedule Enhancement to Improve Outcomes
Condition: Sarcoma
Intervention: Actinomycin D (Dactinomycin); Adriamycin (doxorubicin); CPT-11 (irinotecan); Cabozantinib (XL 184); Camptosar (irinotecan); Dactinomycin (); Doxil (doxorubicin liposome); Etoposide (); Ifosfamide (); Radiotherapy (); Topotecan (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); doxorubicin liposome (); irinotecan ()
CLINICAL TRIAL 23318
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Condition: Sarcoma
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 23716
AVENTINE-1: A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-1418 as a single agent and in combination therapy in patients with locally advanced or metastatic solid tumors
Condition: Multiple
Intervention: AVZO-1418 (); AZD9291 (Osimertinib); Osimertinib (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()
CLINICAL TRIAL 23906
Open-Label, Cohort-Sequential Dose-Escalation and Dose-Confirmation Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of Domatinostat in Combination with Sirolimus in Adolescents and Adults with Relapsed, Refractory Sarcoma and Osteosarcoma
Condition: Sarcoma
Intervention: Domatinostat (); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus ()
CLINICAL TRIAL 23965
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BH3120 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 24010
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); Pembrolizumab (Keytruda); doxorubicin ()
CLINICAL TRIAL 24154
A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination with Imatinib in Participants with Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
Condition: Sarcoma
Intervention: Imatinib (); KQB198 ()
CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()
CLINICAL TRIAL 24394
A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN9025 in Participants with Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Condition: Multiple
Intervention: AN9025 ()
CLINICAL TRIAL 24408
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced soft tissue sarcoma
Condition: Sarcoma
Intervention: Aldesleukin (); Fludarabine (); Lifileucel (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide)